{"nctId":"NCT02369653","briefTitle":"A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase","startDateStruct":{"date":"2015-10-22","type":"ACTUAL"},"conditions":["Lymphoma","Acute Lymphoblastic Leukemia"],"count":512,"armGroups":[{"label":"Apixaban","type":"EXPERIMENTAL","interventionNames":["Drug: Apixaban"]},{"label":"No systemic anticoagulant prophylaxis","type":"PLACEBO_COMPARATOR","interventionNames":["Other: No systemic anticoagulant prophylaxis"]}],"interventions":[{"name":"Apixaban","otherNames":[]},{"name":"No systemic anticoagulant prophylaxis","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com\n\nInclusion Criteria:\n\n* New diagnosis of de novo ALL, lymphomas (T or B cell), or mixed-phenotype acute leukemia\n* Planned 3-4 drug systemic induction chemotherapy with a corticosteroid, vincristine and a single dose or multiple doses of asparaginase, with or without daunorubicin\n* Functioning Central Venous Access Device\n* Must be able to tolerate oral medication or have it administered via an Nasogastric tube (NGT) or GT tube\n* Males and females,age 1 year(365 days) to \\< 18 (17 years and 364 days) years.\n\nExclusion Criteria:\n\n* Subjects scheduled to have \\> 3 Lumbar Punctures over the course of the study treatment period\n* Prior history of documented DVT or PE in the past 3 months\n* Known inherited bleeding disorder or coagulopathy\n* Major surgery \\[excluding Central Venous Access Device (CVAD) replacement and bone marrow aspiration and non-open biopsy\\] within the last 7 days prior to enrollment that may be associated with a risk of bleeding. Open biopsy is considered a major surgery.\n* Uncontrolled severe hypertension at enrollment. Severe hypertension is defined as a systolic or diastolic blood pressure (BP) \\> 5 mm Hg above the 95th percentile as defined by the National High Blood Pressure Education Program Working Group (NHBPEP) established guidelines for the definition of normal and elevated blood pressure in children\n* Extreme hyperleukocytosis, white blood cell (WBC) counts over 200 x 109/L (200,000/microL) at the time of enrollment\n* Liver dysfunction manifested by SGTP (ALT) \\> 5X Upper limit of normal (ULN) and/or Aspartate aminotransferase (AST) \\>5 X ULN and/or direct (conjugated) bilirubin \\> 2X ULN\n* Renal function \\< 30% of normal for age and size as determined by the Schwartz formula\n* International normalized ratio (INR) \\> 1.4 and activated partial thromboplastin time (aPTT) \\> 3 seconds above the upper limit of normal for age, within 1 week prior to enrollment.\n* History of allergy to apixaban or Factor Xa inhibitors\n* History of significant adverse reaction or major bleeding related adverse reaction to other anticoagulant or antiplatelet agents\n* History of any significant drug allergy (such as anaphylaxis or hepatotoxicity\n* Any investigational drug being administered during the study\n\nOther protocol inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Number of Participants With Non-Fatal DVT, PE, and CVST, and VTE-Related-Death","description":"The number of participants with non-fatal deep vein thromboses (DVT) (including asymptomatic and symptomatic), pulmonary embolism (PE), cerebral venous sinus thrombosis (CVST); and venous thromboembolism (VTE) related-death objectively confirmed by a blinded, independent adjudication committee.\n\nSymptomatic events are included during the intended treatment period. Asymptomatic events are included from scans up to Day 40.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]}]},{"type":"PRIMARY","title":"The Number of Participants With Adjudicated Major Bleeding","description":"The number of participants with major bleeding adjudicated by a blinded, independent adjudication committee. Adjudicated major bleeding is defined as bleeding that satisfies one or more of the following criteria:\n\n1. fatal bleeding\n2. clinically overt bleeding associated with a decrease in hemoglobin of at least 20g/L (ie, 2g/dL) in a 24-hour period\n3. bleeding that is retroperitoneal, pulmonary, intracranial, or otherwise involves the CNS; and/or\n4. bleeding that requires surgical intervention in an operating suite, including interventional radiology.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Non-fatal Asymptomatic Deep Vein Thromboses (DVT)","description":"The number of participants with non-fatal asymptomatic deep vein thromboses (DVT) adjudicated by a blinded, independent adjudication committee","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Non-fatal Symptomatic Deep Vein Thromboses (DVT)","description":"The number of participants with non-fatal symptomatic deep vein thromboses (DVT) adjudicated by a blinded, independent adjudication committee","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Non-fatal Pulmonary Embolism (PE)","description":"The number of participants with non-fatal pulmonary embolism (PE) adjudicated by a blinded, independent adjudication committee","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Cerebral Venous Sinus Thrombosis (CVST)","description":"The number of participants with cerebral venous sinus thrombosis (CVST) adjudicated by a blinded, independent adjudication committee","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Venous Thromboembolism (VTE)-Related-death","description":"The number of participants with venous thromboembolism (VTE)-related-death adjudicated by a blinded, independent adjudication committee","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Major and Clinically Relevant Non-Major Bleeding (CRNMB)","description":"The number of participants with major and clinically relevant non-major bleeding (CRNMB) adjudicated by a blinded, independent adjudication committee\n\nCRNM bleeding is defined as bleeding that satisfies one or both of the following:\n\n1. overt bleeding for which blood product is administered and not directly attributable to the subject's underlying medical condition and\n2. bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating room","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participant Deaths","description":"The number of participant deaths adjudicated by a blinded, independent adjudication committee","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With an Arterial Thromboembolic Event","description":"The number of participants with an arterial thromboembolic event including paradoxical embolism and stroke adjudicated by a blinded, independent adjudication committee","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With a CVAD-Related Infection","description":"The number of participants with a central venous access device (CVAD)-related infection adjudicated by a blinded, independent adjudication committee","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants Needing Catheter Replacements During the Study","description":"The number of participants needing catheter replacements during the study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With CVAD Patency Restoration Events After Thrombolytic Therapy Use","description":"The number of participants with central venous access device (CVAD) patency restoration events after thrombolytic therapy use","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number Participants Experiencing Superficial Vein Thrombosis Events","description":"The number participants experiencing superficial vein thrombosis events.\n\nClots that occur in a superficial vein ie, cephalic vein, basilic vein (upper extremity) or saphenous vein (lower extremity) confirmed by radiographic imaging.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Clinically Relevant Non-Major Bleeding Events (CRNMB)","description":"The number of participants with clinically relevant non-major bleeding events (CRNMB) adjudicated by a blinded, independent adjudication committee.\n\nCRNM bleeding is defined as bleeding that satisfies one or both of the following:\n\n1. overt bleeding for which blood product is administered and not directly attributable to the subject's underlying medical condition and\n2. bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating room","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Minor Bleeding Events","description":"The number of participants with minor bleeding events adjudicated by a blinded, independent adjudication committee.\n\nMinor bleeding defined as any overt or macroscopic evidence of bleeding that does not fulfill the criteria for either major bleeding or CRNMB","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Platelet Transfusions Needed During the Study","description":"The number of platelet transfusions needed during the study.\n\nThe events are not adjudicated. A subject could have more than one platelet transfusion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"266","spread":null},{"groupId":"OG001","value":"248","spread":null}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Concentration (Cmax)","description":"The maximum observed concentration (Cmax) was measured to assess the pharmacokinetics of oral or enteric apixaban in pediatric subjects receiving induction chemotherapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.5","spread":"36.5"},{"groupId":"OG001","value":"63.6","spread":"38.6"},{"groupId":"OG002","value":"61.4","spread":"43.9"},{"groupId":"OG003","value":"54.2","spread":"46.8"}]}]}]},{"type":"SECONDARY","title":"Trough Observed Concentration (Cmin)","description":"The trough observed concentration (Cmin) was measured to assess the pharmacokinetics of oral or enteric apixaban in pediatric subjects receiving induction chemotherapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.8","spread":"57.8"},{"groupId":"OG001","value":"18.1","spread":"97.4"},{"groupId":"OG002","value":"12","spread":"142"},{"groupId":"OG003","value":"12.9","spread":"113"}]}]}]},{"type":"SECONDARY","title":"Area Under the Concentration-Time Curve [AUC(TAU)]","description":"The area under the concentration-time curve \\[AUC(TAU)\\] was measured to assess the pharmacokinetics of oral or enteric apixaban in pediatric subjects receiving induction chemotherapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"470","spread":"35.3"},{"groupId":"OG001","value":"510","spread":"42.7"},{"groupId":"OG002","value":"453","spread":"44.8"},{"groupId":"OG003","value":"416","spread":"48.5"}]}]}]},{"type":"SECONDARY","title":"Anti-FXa Activity","description":"Anti-FXa Activity was measured to characterize the relationship between apixaban plasma concentration and anti-FXa activity in pediatric subjects receiving induction chemotherapy","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.3","spread":"16.4"},{"groupId":"OG001","value":"62.2","spread":"19.4"},{"groupId":"OG002","value":"52.8","spread":"16"},{"groupId":"OG003","value":"44.2","spread":"12.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.7","spread":"28.8"},{"groupId":"OG001","value":"72.1","spread":"30.6"},{"groupId":"OG002","value":"77.5","spread":"30.8"},{"groupId":"OG003","value":"87.5","spread":"45.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.2","spread":"8.96"},{"groupId":"OG002","value":"47.5","spread":"10.6"},{"groupId":"OG003","value":"48","spread":"11.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.2","spread":"28"},{"groupId":"OG001","value":"75.3","spread":"33.9"},{"groupId":"OG002","value":"63.9","spread":"21.6"},{"groupId":"OG003","value":"64.8","spread":"25.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":91,"n":250},"commonTop":["Anaemia","Platelet count decreased","Constipation","Alanine aminotransferase increased","Abdominal pain"]}}}